Credit Suisse Downgrades Galapagos NV (GLPG) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Fiserv president resigns, interim leaders named for financial unit
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Cowen Remains Bullish on Galapagos NV (GLPG) After AbbVie (ABBV) Declined to Opt-In for Phase III Development of Filgotinib
September 25, 2015 3:14 PM EDTCowen maintained an Outperform rating on Galapagos NV (NASDAQ: GLPG) following AbbVie's (NYSE: ABBV) decision to terminate its agreement for JAK1 inhibitor filgotinib. The decision was in conjunction with the release of positive data from ABT-494's (JAK1... More
Galapagos NV (GLPG) to Advance Filgotinib to Phase 3 in Rheumatoid Arthritis
September 25, 2015 10:51 AM EDTGalapagos NV (NASDAQ: GLPG) announced today that the Company will be moving filgotinib, its highly selective JAK1 inhibitor, into Phase 3 in rheumatoid arthritis by early 2016. Filgotinib has shown best-in-class efficacy and safety in the DARWIN Phase 2B studies in rheumatoid arthritis and is now fully owned... More
